Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
National Cancer Centre Singapore
InstitutionResearch output, impact & collaborations
National Cancer Centre Singapore is a research organisation in Singapore, SG. OpenAlex records 9,397 works and 979,649 citations for it. 2,742 researchers list it as their most recent affiliation.
9,397
Works
979,649
Citations
2,742
Researchers
56.8
Avg h-index
How has National Cancer Centre Singapore's publication output changed over time?
ScholarIQpublication output · 2012–2024
Output grew0% over the shown period — from 1 works in 2012 to 1 in 2024.
1
1
1
1
2
3
1
1
1
201220132014201720182020202120222024
Who are the most-cited researchers behind National Cancer Centre Singapore?
ScholarIQtop researchers by citations
What are the most-cited papers on National Cancer Centre Singapore?
ScholarIQmost cited works
Ceritinib in <i>ALK</i> -Rearranged Non–Small-Cell Lung Cancer
Alice T. Shaw, Dong-Wan Kim, Ranee Mehra, Daniel S.W. Tan, Enriqueta Felip, Laura Q.M. Chow, D. Ross Camidge, Johan Vansteenkiste, Sunil Sharma, Tommaso De Pas, Gregory J. Riely, Benjamin Solomon, Juergen Wolf, Michael Thomas, Martin Schüler, Geoffrey Liu, Armando Santoro, Yvonne Lau, Meredith A. Goldwasser, Anthony Boral, Jeffrey A. Engelman
New England Journal of Medicine. 20141,477 Citations
Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates
Yannick Simoni, Étienne Becht, Michael Fehlings, Chiew Yee Loh, Si‐Lin Koo, Karen Wei Weng Teng, Joe Yeong, Rahul Nahar, Tong Zhang, Hassen Kared, Kaibo Duan, Nicholas Ang, Michael Poidinger, Yin Yeng Lee, Anis Larbi, Alexis Jiaying Khng, Emile Tan, Cherylin Fu, Ronnie Mathew, Melissa C.C. Teo, Wan Teck Lim, Chee‐Keong Toh, Boon‐Hean Ong, Tina Koh, Axel M. Hillmer, Angela Takano, Tony Kiat Hon Lim, Eng Huat Tan, Weiwei Zhai, Daniel S.W. Tan, Iain Beehuat Tan, Evan W. Newell
Nature. 20181,417 Citations
First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
Jean‐Charles Soria, Daniel S.W. Tan, Rita Chiari, Yi‐Long Wu, Luis Paz‐Ares, Juergen Wolf, Sarayut Lucien Geater, С. В. Орлов, Diego Cortinovis, Chong‐Jen Yu, Maximillian Hochmair, Alexis B. Cortot, Chun‐Ming Tsai, Denis Moro‐Sibilot, Rosario García Campelo, Tracey McCulloch, Paramita Sen, Margaret Dugan, Serafino Pantano, Fabrice Branle, Cristian Massacesi, Gilberto de Castro
The Lancet. 20171,157 Citations
Capmatinib in <i>MET</i> Exon 14–Mutated or <i>MET</i> -Amplified Non–Small-Cell Lung Cancer
Jürgen Wolf, Takashi Seto, Ji‐Youn Han, Noemı́ Reguart, Edward B. Garon, Harry J.M. Groen, Daniel S.W. Tan, Toyoaki Hida, Maja J.A. de Jonge, Sergey Orlov, Egbert F. Smit, Pierre-Jean Souquet, Johan Vansteenkiste, Maximilian J. Hochmair, Enriqueta Felip, Makoto Nishio, Michael Thomas, Kadoaki Ohashi, Ryo Toyozawa, Tobias R. Overbeck, Filippo de Marinis, Tae Min Kim, Eckart Laack, Anna Robeva, Sylvie Le Mouhaër, Maeve Waldron-Lynch, B. Sankaran, O. Alejandro Balbin, Xiaoming Cui, Monica Giovannini, Mikhail Akimov, Rebecca S. Heist
New England Journal of Medicine. 20201,009 CitationsOPEN ACCESS
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
Lori J. Wirth, Eric J. Sherman, Bruce Robinson, Benjamin Solomon, Hyunseok Kang, Jochen H. Lorch, Francis P. Worden, Marcia S. Brose, Jyoti D. Patel, Sophie Leboulleux, Yann Godbert, Fabrice Barlési, John C. Morris, Taofeek K. Owonikoko, Daniel S.W. Tan, Oliver Gautschi, Jared Weiss, Christelle de la Fouchardière, Mark E. Burkard, Janessa Laskin, Matthew H. Taylor, Matthias Kroiß, Jacques Médioni, Jonathan W. Goldman, Todd M. Bauer, Benjamin Levy, Viola W. Zhu, Nehal J. Lakhani, Víctor Moreno, Kevin Ebata, Michele Nguyen, Dana Heirich, Edward Y. Zhu, Xin Huang, Luxi Yang, Jennifer Kherani, S. Michael Rothenberg, Alexander Drilon, Vivek Subbiah, Manisha H. Shah, Maria E. Cabanillas
New England Journal of Medicine. 2020788 CitationsOPEN ACCESS
How much of the research on National Cancer Centre Singapore is open access?
ScholarIQopen access share
50%OPEN ACCESS
Gold
8%
Green
17%
Hybrid
0%
Bronze
25%
Closed
50%